Recep Halit Tokac

Recep Halit Tokac

Auto-generated profile, based on publicly available information

Recep Halit Tokac

Department of Nuclear Medicine Ege University Faculty of Medicine Izmir Turkey

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 August 2025 in Cancer Medicine
Verified
Journal Article
Open access
RTRecep Halit Tokac
Recep Halit Tokac
ETEkin Cemre Bayram Tokac
Ekin Cemre Bayram Tokac
UYUlkem Yararbas
Ulkem Yararbas
AAAyca Aykut
Ayca Aykut
ADAsude Durmaz
Asude Durmaz
AAAziz Murat Argon
Aziz Murat Argon
Background: This study investigated the relationship between circulating tumor DNA (ctDNA) parameters and metabolic parameters from FDG PET/CT in advanced breast cancer (ABC) patients.Methods: In this retrospective single‐center study, 47 ABC patients who underwent both liquid biopsy and FDG PET/CT were analyzed.Results: Results showed that 27 patients (57.4%) had detectable ctDNA. Patients with detectable ctDNA demonstrated significantly higher whole‐body metabolic tumor volume (WB‐MTV) (p = 0.002) and whole‐body total lesion glycolysis (WB‐TLG) (p = 0.006) compared to those without ctDNA, while no significant difference was found in SUVmax or SUVmean. A moderate correlation was observed between variant allele frequency (VAF) values and metabolic parameters: maximum VAF correlated with SUVmax, WB‐MTV, and WB‐TLG (r = 0.407, p = 0.005; r = 0.457, p = 0.001; r = 0.415, p = 0.004, respectively). Mean VAF correlated with SUVmax, WB‐MTV, and WB‐TLG (r = 0.406, p = 0.005; r = 0.446, p = 0.002; r = 0.404, p = 0.005, respectively). The total VAF correlated with SUVmax, WB‐MTV, and WB‐TLG (r = 0.394, p = 0.006; r = 0.465, p = 0.001; r = 0.430, p = 0.003, respectively). When excluding patients without detectable ctDNA, the correlation between VAF values and WB‐MTV, WB‐TLG disappeared, while the correlation with SUVmax persisted. Total alteration number in ctDNA showed a moderate correlation with WB‐MTV and WB‐TLG (r = 0.563, p < 0.001; r = 0.459, p = 0.001, respectively). Correlation with WB‐MTV remained significant when excluding patients without detectable ctDNA (r = 0.500, p = 0.008).Conclusions: These findings suggest that metabolic tumor burden correlates with ctDNA detection and characteristics, potentially offering complementary information for disease monitoring, treatment selection, and response assessment in ABC. The combined use of these parameters may improve prognostic evaluation and guide personalized treatment strategies.